...
search icon
autl-img

Autolus Therapeutics Ltd Share Price

AUTL
NSQ
$1.67
+$0.03
(1.83%)
1D
Industry: Biotechnology Sector: Health Care

Autolus Therapeutics Ltd Analyst Forecast

Autolus Therapeutics Ltd Share Price Chart

Autolus Therapeutics Ltd Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$436.47M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.17M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.99
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.1 L
$2.7 H
$1.67

About Autolus Therapeutics Ltd, Common Stock

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Autolus Therapeutics Ltd Stock Returns

Time FrameAUTLSectorS&P500
1-Week Return17.14%-0.26%0.42%
1-Month Return15.49%1.2%1.02%
3-Month Return33.33%3.86%4.93%
6-Month Return-5.2%14.37%7.32%
1-Year Return-15.9%6.82%12.16%
3-Year Return-16.33%20.71%71.63%
5-Year Return-76.4%37.78%76.95%
10-Year Return-93.44%135.17%252.5%

Autolus Therapeutics Ltd Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue1.72M1.51M6.19M1.70M10.12M[{"date":"2020-12-31","value":16.95,"profit":true},{"date":"2021-12-31","value":14.89,"profit":true},{"date":"2022-12-31","value":61.21,"profit":true},{"date":"2023-12-31","value":16.78,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue134.89M128.65M137.22M6.57M141.02M[{"date":"2020-12-31","value":95.65,"profit":true},{"date":"2021-12-31","value":91.23,"profit":true},{"date":"2022-12-31","value":97.31,"profit":true},{"date":"2023-12-31","value":4.66,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(133.17M)1.51M6.19M1.70M(130.90M)[{"date":"2020-12-31","value":-2150.03,"profit":false},{"date":"2021-12-31","value":24.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":27.41,"profit":true},{"date":"2024-12-31","value":-2113.34,"profit":false}]
Gross Margin(7765.19%)100.00%100.00%100.00%(1293.48%)[{"date":"2020-12-31","value":-7765.19,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-1293.48,"profit":false}]
Operating Expenses169.96M141.88M149.09M181.40M110.53M[{"date":"2020-12-31","value":93.69,"profit":true},{"date":"2021-12-31","value":78.21,"profit":true},{"date":"2022-12-31","value":82.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":60.93,"profit":true}]
Operating Income(303.13M)(140.37M)(142.89M)(179.70M)(241.43M)[{"date":"2020-12-31","value":-30313300000,"profit":false},{"date":"2021-12-31","value":-14037400000,"profit":false},{"date":"2022-12-31","value":-14289300000,"profit":false},{"date":"2023-12-31","value":-17970100000,"profit":false},{"date":"2024-12-31","value":-24142600000,"profit":false}]
Total Non-Operating Income/Expense137.41M(2.51M)(12.87M)(35.18M)45.35M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1.82,"profit":false},{"date":"2022-12-31","value":-9.37,"profit":false},{"date":"2023-12-31","value":-25.6,"profit":false},{"date":"2024-12-31","value":33.01,"profit":true}]
Pre-Tax Income(166.26M)(142.04M)(148.57M)(208.40M)(219.13M)[{"date":"2020-12-31","value":-16625700000,"profit":false},{"date":"2021-12-31","value":-14203800000,"profit":false},{"date":"2022-12-31","value":-14856700000,"profit":false},{"date":"2023-12-31","value":-20840200000,"profit":false},{"date":"2024-12-31","value":-21913400000,"profit":false}]
Income Taxes(24.16M)58.00K272.00K(19.00K)1.53M[{"date":"2020-12-31","value":-1581.35,"profit":false},{"date":"2021-12-31","value":3.8,"profit":true},{"date":"2022-12-31","value":17.8,"profit":true},{"date":"2023-12-31","value":-1.24,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(142.09M)(142.10M)(148.84M)(208.38M)(220.66M)[{"date":"2020-12-31","value":-14209400000,"profit":false},{"date":"2021-12-31","value":-14209600000,"profit":false},{"date":"2022-12-31","value":-14883900000,"profit":false},{"date":"2023-12-31","value":-20838300000,"profit":false},{"date":"2024-12-31","value":-22066200000,"profit":false}]
Income From Continuous Operations(142.09M)(142.10M)(148.84M)(158.16M)(220.66M)[{"date":"2020-12-31","value":-14209400000,"profit":false},{"date":"2021-12-31","value":-14209600000,"profit":false},{"date":"2022-12-31","value":-14883900000,"profit":false},{"date":"2023-12-31","value":-15816300000,"profit":false},{"date":"2024-12-31","value":-22066200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(142.09M)(142.10M)(148.84M)(208.38M)(220.66M)[{"date":"2020-12-31","value":-14209400000,"profit":false},{"date":"2021-12-31","value":-14209600000,"profit":false},{"date":"2022-12-31","value":-14883900000,"profit":false},{"date":"2023-12-31","value":-20838300000,"profit":false},{"date":"2024-12-31","value":-22066200000,"profit":false}]
EPS (Diluted)(2.77)(1.97)(1.57)(1.20)(0.86)[{"date":"2020-12-31","value":-277,"profit":false},{"date":"2021-12-31","value":-197,"profit":false},{"date":"2022-12-31","value":-157,"profit":false},{"date":"2023-12-31","value":-120,"profit":false},{"date":"2024-12-31","value":-86,"profit":false}]

Autolus Therapeutics Ltd Ratios

Autolus Therapeutics Ltd Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

AUTL
Cash Ratio 4.42
Current Ratio 6.19
Quick Ratio 5.86

Autolus Therapeutics Ltd Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AUTL
ROA (LTM) -22.99%
ROE (LTM) -60.56%

Autolus Therapeutics Ltd Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AUTL
Debt Ratio Lower is generally better. Negative is bad. 0.60
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.40

Autolus Therapeutics Ltd Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AUTL
Trailing PE NM
Forward PE NM
P/S (TTM) 8.12
P/B 1.41
Price/FCF NM
EV/R 1.44
EV/Ebitda 0.03

FAQs

What is Autolus Therapeutics Ltd share price today?

Autolus Therapeutics Ltd (AUTL) share price today is $1.67

Can Indians buy Autolus Therapeutics Ltd shares?

Yes, Indians can buy shares of Autolus Therapeutics Ltd (AUTL) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AUTL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Autolus Therapeutics Ltd be purchased?

Yes, you can purchase fractional shares of Autolus Therapeutics Ltd (AUTL) via the Vested app. You can start investing in Autolus Therapeutics Ltd (AUTL) with a minimum investment of $1.

How to invest in Autolus Therapeutics Ltd shares from India?

You can invest in shares of Autolus Therapeutics Ltd (AUTL) via Vested in three simple steps:

  • Click on Sign Up or Invest in AUTL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Autolus Therapeutics Ltd shares
What is Autolus Therapeutics Ltd 52-week high and low stock price?

The 52-week high price of Autolus Therapeutics Ltd (AUTL) is $2.7. The 52-week low price of Autolus Therapeutics Ltd (AUTL) is $1.1.

What is Autolus Therapeutics Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Autolus Therapeutics Ltd (AUTL) is

What is Autolus Therapeutics Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Autolus Therapeutics Ltd (AUTL) is 1.41

What is Autolus Therapeutics Ltd dividend yield?

The dividend yield of Autolus Therapeutics Ltd (AUTL) is 0.00%

What is the Market Cap of Autolus Therapeutics Ltd?

The market capitalization of Autolus Therapeutics Ltd (AUTL) is $436.47M

What is Autolus Therapeutics Ltd's stock symbol?

The stock symbol (or ticker) of Autolus Therapeutics Ltd is AUTL

How Can Investors Use Autolus Therapeutics Ltd Share Price Data for Long-Term Investment Decisions?

Consider the share price of Autolus Therapeutics Ltd as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Autolus Therapeutics Ltd has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Autolus Therapeutics Ltd shares for Indian investors?

When investing in Autolus Therapeutics Ltd shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Autolus Therapeutics Ltd stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Autolus Therapeutics Ltd share price with other stocks in the same sector?

Rather than merely checking the share price of Autolus Therapeutics Ltd and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Autolus Therapeutics Ltd stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top